What's Happening?
Skylark Bio, a biotechnology company focused on developing genetic medicines for hearing loss, is set to present new preclinical data for its Pendrin gene therapy program, SKY-PEN, at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting.
The SKY-PEN program targets SLC26A4-related hearing loss, a significant genetic cause of severe-to-profound deafness in children and young adults. The therapy has shown promising results in preclinical studies, demonstrating dose-dependent improvements in hearing across multiple mouse models. Skylark Bio's approach involves precise, micro-dose delivery with minimal systemic exposure, aiming to improve hearing and alter long-term outcomes for individuals with Pendred syndrome and related conditions.
Why It's Important?
The development of the SKY-PEN gene therapy program is significant as it addresses a major unmet need in the treatment of genetic hearing loss. Currently, there are no approved therapies for SLC26A4-related hearing loss, which affects thousands globally. Skylark Bio's innovative approach could potentially transform the treatment landscape for patients with inherited hearing loss, offering a first-in-class opportunity to improve hearing and quality of life. The success of this program could pave the way for further advancements in genetic medicine, particularly for monogenic diseases where precise local delivery and cell-specific expression are crucial.
What's Next?
Skylark Bio is advancing the SKY-PEN program toward IND-enabling studies, with plans to initiate first-in-human studies for its lead GJB2 program by mid-2026. The company is also expanding its platform to address additional hearing and central nervous system indications. The upcoming presentation at ASGCT 2026 will provide further insights into the program's progress and potential impact, potentially attracting interest from researchers, clinicians, and investors in the field of genetic medicine.
